GC Biopharma Corp
Clinical trials sponsored by GC Biopharma Corp, explained in plain language.
A biopharmaceutical company developing plasma-derived and recombinant therapies.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Can a new vaccine shield against COVID-19? a trial aims to find out Results expected May 2027 (estimated)
- Can a direct brain infusion slow sanfilippo syndrome? Results expected Jun 2027 (estimated)
- New chickenpox vaccine shows promise in large Kids' trial Results expected Aug 2027 (estimated)
-
Can a new vaccine shield against COVID-19? a trial aims to find out
Vaccine OngoingThis trial tests an experimental COVID-19 vaccine called GC4006A in healthy adults aged 19 to 64. The goal is to see if the vaccine is safe and triggers an immune response. Participants receive a single shot of either the vaccine or a placebo, and researchers monitor for side eff…
Phase 1 • Sponsor: GC Biopharma Corp • Aim: Vaccine
Last updated Jul 29, 2026 00:00 UTC
-
Can a direct brain infusion slow sanfilippo syndrome?
Disease control OngoingThis trial tests an experimental enzyme replacement called GC1130A in children with Sanfilippo syndrome type A, a rare genetic disease that damages the brain. The enzyme is given through a small device placed under the scalp that delivers it directly into the fluid around the bra…
Phase 1 • Sponsor: GC Biopharma Corp • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC